Clinical Significance of Monitoring by Interferon-Gamma Releasing Assay (IGRA) in Patients with Non-Small Cell Lung Cancer receiving Checkpoint Inhibitor Treatment
Not Applicable
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000031881
- Lead Sponsor
- Osaka Prefectural Hospital Organization Osaka Habikino Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient with an active heterochronous or synchronous overlap cancer (carcinoma-insitu or cured intramucosal canceris excluded from overlap cancer) 2 Patient with active liver disease (ex. HBV-DNA positive, autoimmune hepatitis, anliver cirrhosis). 3 Female patient with the possibility (intention) of the pregnancy. Patient whom the Doctor in charge judged to be inappropriate as an object of this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association between IFN-gamm and efficacy, immune-related adverse events, or Hyper progressive Disease in Patients with Non-Small Cell Lung Cancer receiving ICI
- Secondary Outcome Measures
Name Time Method